未知生产厂商
Orally administered bradykinin B2 receptor antagonist under development by Pharvaris N.V. for hereditary angioedema (HAE). In the pivotal Phase 3 CHAPTER-3 study, once-daily deucrictibant extended-release (XR) 40 mg reduced monthly HAE attack rates by 83% versus placebo (p<0.0001); a prophylaxis New Drug Application submission is planned for the first half of 2027.
Orally administered bradykinin B2 receptor antagonist under development by Pharvaris N.V. for hereditary angioedema (HAE). In the pivotal Phase 3 CHAPTER-3 study, once-daily deucrictibant extended-release (XR) 40 mg reduced monthly HAE attack rates by 83% versus placebo (p<0.0001); a prophylaxis New Drug Application submission is planned for the first half of 2027.
Bradykinin B2 receptor antagonist. Deucrictibant blocks the bradykinin B2 receptor, the downstream effector of vascular permeability that drives swelling attacks regardless of which upstream pathway generates bradykinin.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
